Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Henan Shijia Photons Technology
688313
5
Hunan Airbluer Environmental Protection Technology
301259
US OptionsDetailed Quotes
BIIB250417P116000
- 0.95
- 0.000.00%
15min DelayClose Apr 17 16:00 ET
0.00High0.00Low
0.95Open0.95Pre Close0 Volume22 Open Interest116.00Strike Price0.00Turnover1382.35%IV3.00%PremiumApr 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-3DDays to Expiry0.95Extrinsic Value100Contract SizeAmericanOptions Type-0.2973Delta0.0701Gamma124.85Leverage Ratio-262.4863Theta0.0000Rho-37.12Eff Leverage0.0012Vega
Biogen Newsroom
BMO Capital Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $128
BMO Capital Adjusts Biogen Price Target to $128 From $139
Wells Fargo Maintains Biogen(BIIB.US) With Hold Rating, Maintains Target Price $140
Wedbush Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $121
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Biogen Unlikely to Receive Boost From Leqembi Approval in EU -- Market Talk
Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion
EC Authorises Eisai and Biogen's Lecanemab for Alzheimer's
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday
Express News | Biogen : Wedbush Cuts Target Price to $121 From $135
Express News | Needham Reiterates Hold on Biogento Hold
Biogen Analyst Ratings
Drug to Treat Underlying Causes of Alzheimer's Gets EU Marketing Approval
Needham Maintains Biogen(BIIB.US) With Hold Rating
Biogen's Hold Rating Amidst Restrictive EU Approval for Leqembi and Potential Stock Impact
Biogen, Eisai's Alzheimer's Drug Leqembi Approved in EU
Fund Update: SG Americas Securities, LLC Opened a $98.5M Position in $BIIB Stock
Piper Sandler Maintains Biogen(BIIB.US) With Hold Rating, Maintains Target Price $135
Uncertainty looms, which biotech stocks in the U.S. are expected to break through? Goldman Sachs provides the answer.
Goldman Sachs suggests focusing on companies that are less affected by tariffs and policy risks, such as Vertex Pharmaceuticals (VRTX.US) and Alnylam Pharmaceuticals (ALNY.US).
Leqembi∇ (Lecanemab) Is the First Medicine That Slows Progression of Early Alzheimer's Disease to Be Authorized in the European Union
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now